Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01232842|
Recruitment Status : Completed
First Posted : November 2, 2010
Last Update Posted : July 11, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: cytogenetic analysis Other: HUMARA assay Other: fluorescence activated cell sorting Other: laboratory biomarker analysis|
- Determine the frequency of acute myeloid leukemia (AML) that originates in CD33+ precursors or in which uncontrolled growth is restricted to CD33+ precursors.
OUTLINE: Cryopreserved acute myeloid leukemia cell samples are separated from endothelial cell by fluorescent-activated cell sorting (FACS) and analyzed for X-chromosome inactivation patterns by cytogenetic/molecular analysis and/or Humara assay.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||July 2016|
- Frequency of AML that originate in CD33+ or in which uncontrolled growth is restricted to CD33+ precursors
- Extent of clonal hematopoiesis in small numbers of AML cells
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01232842
|Principal Investigator:||Roland Walter, MD, PhD||Fred Hutchinson Cancer Research Center|